- Ring The Bell
- Posts
- The $5 Stock at the Forefront of the “Everything Cure”
The $5 Stock at the Forefront of the “Everything Cure”
You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.
Editor’s Note: Today you’re getting a peek behind the curtain - special, one-off access to the latest issue of the investment report that paid members of Benzinga Research get every week. If you want to get more of these, and access to top trader Matt Maley’s picks, sign up below. Enjoy!
Last Friday, scientists announced a new, one-time cure for cystic fibrosis.
In May, a 12-year-old boy became the first patient ever to receive a newly approved gene therapy to cure sickle cell anemia, a disease affecting 20,000 Americans.
That month, researchers at the Fred Hutch Cancer Center announced that a gene therapy had removed 90% or more of herpes infections in pre-clinical trials… and in February, a study from Stanford a new genetic treatment’s success in modifying cells to fight cancerous cells more effectively.
For now, gene-editing is an expensive treatment (the cure for sickle cell anemia costs $2-3 million, for instance). But costs are expected to fall dramatically as more efficient and novel treatments are discovered, refined, and commercialized.
Investors who act on this trend today can look forward to knowing that their capital is at work alleviating tremendous human suffering down the road… not to mention, potentially explosive profits as the revolution in genetic editing unfolds.
Wall Street legend Matt Maley, with a 7,847% gain in 2022, has FINALLY revealed his #1 AI stock pick.
It's NOT a tech company…
But it's perfectly positioned for the AI revolution.
July 23rd is your deadline.